Clinical Trials
38 trialsPhase II Trial of Ribociclib and Everolimus in Advanced Dedifferentiated Liposarcoma (DDL) and Leiomyosarcoma (LMS)
Fox Chase Cancer Center
A Study of Pembrolizumab in People With Ultra-Rare Sarcomas
Memorial Sloan Kettering Cancer Center
Testing the Addition of Cemiplimab to Palbociclib for the Treatment of Advanced Dedifferentiated Liposarcoma
Alliance for Clinical Trials in Oncology
DOSa
M.D. Anderson Cancer Center
Nivolumab With and Without Ipilimumab and Radiation Therapy in Treating Patients With Recurrent or Resectable Undifferentiated Pleomorphic Sarcoma or Dedifferentiated Liposarcoma Before Surgery
M.D. Anderson Cancer Center
TRABEPIO
Mario Negri Institute for Pharmacological Research
PROSARC-1
Oslo University Hospital
PROSARC-2
Oslo University Hospital
TAIS
Fudan University
NeoSarc
Gustave Roussy, Cancer Campus, Grand Paris
A Study of Etrumadenant and Zimberelimab in People With Dedifferentiated Liposarcoma
Memorial Sloan Kettering Cancer Center
Palbociclib and INCMGA00012 in People With Advanced Liposarcoma
Memorial Sloan Kettering Cancer Center
A Phase II Study of Eribulin and Pembrolizumab in Soft Tissue Sarcomas
Dana-Farber Cancer Institute
PERELI
Lund University Hospital
Study of Abemaciclib in Dedifferentiated Liposarcoma
Memorial Sloan Kettering Cancer Center
APX005M and Doxorubicin in Advanced Sarcoma
Columbia University
Efatutazone Dihydrochloride in Treating Patients With Previously Treated Myxoid Liposarcoma That Cannot Be Removed by Surgery
Alliance for Clinical Trials in Oncology
First-line Treatment of Advanced/unresectable DDLPS
Fudan University
Sitravatinib in Advanced Liposarcoma and Other Soft Tissue Sarcomas
Columbia University
ATX-101
Columbia University
SARC024: A Blanket Protocol to Study Oral Regorafenib in Patients With Selected Sarcoma Subtypes
Sarcoma Alliance for Research through Collaboration
Doxorubicin With Upfront Dexrazoxane for the Treatment of Advanced or Metastatic Soft Tissue Sarcoma
Washington University School of Medicine
Rosiglitazone in Treating Patients With Liposarcoma
Dana-Farber Cancer Institute
Pazopanib Hydrochloride and Topotecan Hydrochloride in Treating Patients With Metastatic Soft Tissue and Bone Sarcomas
Northwestern University
Phase 2 Study of 9-ING-41 With Chemotherapy in Sarcoma
Brown University
Gemcitabine With or Without Pazopanib in Treating Patients With Refractory Soft Tissue Sarcoma
OHSU Knight Cancer Institute
A Phase 2 Study of 9-ING-41Combined With Chemotherapy in Adolescents and Adults With Advanced Sarcomas
Brown University
SINDIR
Maria Sklodowska-Curie National Research Institute of Oncology
APLIPO
Institut Bergonié
UN-RESARC
Maria Sklodowska-Curie National Research Institute of Oncology
Activity and Tolerability of Pazopanib in Advanced and/or Metastatic Liposarcoma. A Phase II Clinical Trial
Grupo Espanol de Investigacion en Sarcomas
PD0332991 (Palbociclib) in Patients With Advanced or Metastatic Liposarcoma
Memorial Sloan Kettering Cancer Center
Bevacizumab and Radiation Therapy for Sarcomas
Massachusetts General Hospital
Study of Pazopanib in the Treatment of Surgically Unresectable or Metastatic Liposarcoma
Vector Oncology
Troglitazone in Treating Patients With Liposarcoma
Dana-Farber Cancer Institute
A Phase II Study Assessing Efficacy & Safety of Ribociclib in Patients With Advanced Well/Dedifferentiated Liposarcoma
Hadassah Medical Organization
Sunitinib in Treating Patients With Metastatic, Locally Advanced, or Locally Recurrent Sarcomas
Memorial Sloan Kettering Cancer Center
Phase II Study of Sunitinib Malate for Metastatic and/or Surgically Unresectable Soft Tissue Sarcoma
H. Lee Moffitt Cancer Center and Research Institute